Broker’s call: Dr Lal Pathlabs (Buy)
Target: ₹3,400 CMP: ₹3,053.50 Dr Lal Pathlabs’ (DLPL) Q2-FY25 margins expanded by 110bps y-o-y on the back of improving contribution
Continue readingThe Number One Finance & Business Blog!
Target: ₹3,400 CMP: ₹3,053.50 Dr Lal Pathlabs’ (DLPL) Q2-FY25 margins expanded by 110bps y-o-y on the back of improving contribution
Continue readingThe water level in 155 major reservoirs in the country remained unchanged for the third consecutive week at 87 per
Continue readingThe Reserve Bank of India (RBI) has delivered a sharp message to Microfinance Institutions (MFIs), urging them to realign their
Continue readingCoromandel International Limited, a Murugappa group company that provides agricultural solutions, has reported a decline in net profit for the
Continue readingPNB Housing Finance Limited (PNBHFL) on Thursday reported a 22.7 per cent increase in consolidated net profit for the quarter
Continue readingSEBI’s recent circular on investments from land bordering countries through alternative investment funds (AIFs) may add another layer of complexity
Continue readingAgritech firm AgroStar has announced a strategic partnership with Spanish company Biorizon Biotech to bring advanced biological and biocontrol products
Continue readingSuryoday Small Finance Bank reported a 10 per cent year-on-year (y-o-y) decline in second quarter (Q2FY25) net profit at ₹45
Continue readingEven as the Union Food Minister Pralhad Joshi has assured that rice procurement in Punjab will be as per target,
Continue readingThe rupee stayed stuck at its near-record low of 84.07 (provisional) against the US dollar on Thursday as surging crude
Continue reading